Filing Flows › Insmed (INSM) › Q3 2026 › vs Q2 2026
Insmed (INSM) Q3 2026 vs Q2 2026 (quarter over quarter)
Insmed's revenue rose $98.9M (+23%) from $425M in Q2 2026 to $524M in Q3 2026. The biggest changes: BRINSUPRI +$90.9M (+29%); ARIKAYCE +$8.1M (+7%).
Insmed, Q3 2026: revenue $524M (+268% year over year), operating margin -17.0%, net loss $100M, operating cash flow −$36.5M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| BRINSUPRI | $400M | $309M | $90.9M | +29% |
| ARIKAYCE | $124M | $116M | $8.1M | +7% |
| Revenue | $524M | $425M | $98.9M | +23% |
| Net loss | $100M | $13.2M | $87.1M | +658% |
| Costs & expenses | $625M | $439M | $186M | +42% |
| Operating costs | $614M | $427M | $187M | +44% |
| Interest & other, net | $8.3M | $9.8M | −$1.5M | -16% |
| Income tax | $2.7M | $1.9M | $797K | +43% |
| Operating cash sources | $100M | $13.2M | $87.1M | +658% |
| Depreciation & amortization | $8.4M | $5.3M | $3.1M | +60% |
| Share-based compensation | $41.2M | $41.3M | −$34K | -0.1% |
| Working capital & other | $14.2M | −$122M | $136M | — |
| Cash used in operations | $36.5M | $88.8M | −$52.4M | -59% |
| Net loss absorbed | $100M | $13.2M | $87.1M | +658% |
Questions
How much did Insmed's revenue grow quarter over quarter in Q3 2026?
Insmed's revenue rose $98.9M (+23%) from $425M in Q2 2026 to $524M in Q3 2026.
What drove Insmed's revenue change in Q3 2026?
BRINSUPRI +$90.9M (+29%); ARIKAYCE +$8.1M (+7%).